ENOB Stock Price, Enochian Biosciences, . Quote, Chart

ENOB Stock Price

View Fullscreen

ENOB RSI Chart

ENOB Valuation

Market Cap

84.2M

Price/Earnings (Trailing)

-1.56

Price/Sales (Trailing)

2.0K

EV/EBITDA

-2.06

Price/Free Cashflow

-7.76

ENOB Price/Sales (Trailing)

ENOB Profitability

EBT Margin

-95599.30%

Return on Equity

-31.99%

Return on Assets

-25.4%

Free Cashflow Yield

-12.89%

ENOB Fundamentals

ENOB Revenue

Revenue (TTM)

43.1K

ENOB Earnings

Earnings (TTM)

-53.9M

Earnings Growth (Yr)

-293.33%

Earnings Growth (Qtr)

-275.89%

Breaking Down ENOB Revenue

Last 7 days

20.3%

Last 30 days

14.7%

Last 90 days

-43.0%

Trailing 12 Months

-71.7%

How does ENOB drawdown profile look like?

ENOB Financial Health

Current Ratio

0.06

ENOB Investor Care

Shares Dilution (1Y)

153.08%

Diluted EPS (TTM)

-0.78

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2016	43.7K	43.1K	0	0
2015	0	0	0	43.7K
2013	55.3K	47.8K	40.3K	32.8K
2012	0	0	0	62.8K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Enochian Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 26, 2023	sindlev rene	acquired	1,000,000	0.53	1,886,790	-
Mar 17, 2023	sindlev rene	acquired	1,000,000	1.14	877,193	-
Oct 13, 2022	weird science llc	acquired	-	-	1,216,470	-
Oct 13, 2022	william anderson wittekind	acquired	-	-	1,216,470	-
Jun 08, 2022	sindlev rene	sold	-	-	-125,000	-
Jun 08, 2022	sindlev rene	sold	-	-	-128,493	-
May 18, 2022	sindlev rene	bought	1,027,940	8.00	128,493	-
May 18, 2022	gumrukcu serhat	sold	-2,027,940	8.00	-253,493	-
May 18, 2022	sindlev rene	bought	1,000,000	8.00	125,000	-
Apr 15, 2022	weird science llc	sold	-	-	-4,961,360	-

Which funds bought or sold ENOB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Squarepoint Ops LLC	new	-	39,127	39,127	-%
May 15, 2024	Cubist Systematic Strategies, LLC	new	-	52,984	52,984	-%
May 15, 2024	BOOTHBAY FUND MANAGEMENT, LLC	sold off	-100	-64,668	-	-%
May 15, 2024	Brevan Howard Capital Management LP	new	-	86,528	86,528	-%
May 15, 2024	683 Capital Management, LLC	sold off	-100	-233,648	-	-%
May 15, 2024	Laurion Capital Management LP	unchanged	-	-31,971	162,933	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	90,792	90,792	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	132	377,707	778,122	-%
May 15, 2024	Royal Bank of Canada	new	-	14,000	14,000	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	2,278	770,481	811,282	-%

Are Funds Buying or Selling ENOB?

Are funds buying ENOB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ENOB

No. of Funds

Unveiling Enochian Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 08, 2024	william anderson wittekind	13.1%	18,956,376	SC 13D/A
Feb 22, 2024	abildgaard ole	7.6%	11,157,447	SC 13G/A
Feb 16, 2024	sindlev rene	10.28%	14,945,971	SC 13D/A
Feb 16, 2024	william anderson wittekind	13.2%	18,956,376	SC 13D/A
Jan 24, 2024	sindlev rene	20.9%	14,945,971	SC 13D/A
Jan 24, 2024	sindlev rene	23.3%	13,861,471	SC 13D/A
Jan 24, 2024	sindlev rene	19.6%	11,031,280	SC 13D/A
Jan 24, 2024	sindlev rene	18.6%	9,702,808	SC 13D/A
Jan 24, 2024	sindlev rene	20.9%	9,685,251	SC 13D/A
Jan 24, 2024	sindlev rene	24.2%	9,515,137	SC 13D/A

Recent SEC filings of Enochian Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
Apr 30, 2024	8-K	Current Report
Apr 25, 2024	8-K	Current Report
Apr 24, 2024	8-K/A	Current Report
Apr 08, 2024	SC 13D/A	13D - Major Acquisition
Mar 19, 2024	4	Insider Trading
Mar 13, 2024	3	Insider Trading
Mar 13, 2024	4	Insider Trading
Mar 13, 2024	8-K	Current Report
Mar 07, 2024	8-K	Current Report

Enochian Biosciences, Inc. News

Latest updates

Enochian Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2016Q2	2016Q1	2015Q4	2013Q4	2013Q3	2013Q2	2013Q1	2012Q4
Revenue	-	244	-	42,525	285	925	-	31,558	-
Gross Profit	-	213	-	37,281	-40,528	-15,273	-36,928	16,198	-
Income Taxes	1276.7%	397,824	-33,808	-340,103	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	265.9%	212	58.00	58.00	58.00	79.00	80.00	83.00	85.00	180	183	184	190	174	173	175	178	181	178	181	180	178
Current Assets	-49.2%	1.00	2.00	2.00	3.00	4.00	5.00	8.00	10.00	12.00	15.00	15.00	21.00	5.00	4.00	6.00	9.00	11.00	9.00	11.00	12.00	11.00
Cash Equivalents	28.2%	0.00	0.00	1.00	2.00	3.00	4.00	8.00	9.00	11.00	14.00	15.00	21.00	5.00	3.00	6.00	9.00	11.00	9.00	11.00	12.00	10.00
Net PPE	-1.6%	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Goodwill	1310.5%	164	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00
Liabilities	202.9%	44.00	14.00	11.00	12.00	13.00	13.00	13.00	12.00	19.00	18.00	-	15.00	11.00	11.00	11.00	12.00	10.00	7.00	8.00	7.00	25.00
Current Liabilities	51.7%	21.00	14.00	10.00	11.00	12.00	11.00	7.00	6.00	8.00	6.00	1.00	2.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00
Shareholder's Equity	286.7%	169	44.00	47.00	47.00	66.00	67.00	70.00	73.00	161	166	167	175	162	162	164	166	170	171	172	173	153
Retained Earnings	-6.6%	-274	-257	-253	-244	-220	-216	-212	-204	-114	-107	-101	-90.91	-73.55	-69.52	-66.58	-64.19	-60.09	-58.58	-56.86	-52.77	-53.94
Additional Paid-In Capital	46.8%	442	301	300	291	287	283	282	277	275	274	268	266	236	231	231	230	230	230	229	226	206
Accumulated Depreciation	-	1.00	-	-	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	119.4%	147	67.00	66.00	64.00	58.00	56.00	55.00	53.00	53.00	53.00	52.00	52.00	48.00	47.00	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	45.00	-	-	-	243	-	-	-	83.00	-	-	-	69.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	16.3%	-2,633	-3,146	-2,777	-2,261	-3,307	-3,551	-2,653	-3,050	-2,784	-4,620	-5,276	-13,028	-2,330	-2,496	-2,755	-2,245	-3,838	-2,575	-1,800	-2,218	-2,737
Share Based Compensation	86.3%	1,862	999	984	721	968	820	1,026	-110	578	2,043	2,728	186	352	359	326	-11.25	-28.09	690	234	162	97.00
Cashflow From Investing	-59.8%	-91.60	-57.33	-1,057	-6.14	-	-	-	-	-	-	-5.16	-38.17	-	-10.72	-	-10.45	-41.69	-63.70	-68.62	17.00	-92.63
Cashflow From Financing	-7.2%	2,641	2,847	2,563	1,248	2,109	-300	1,458	1,070	230	2,951	-	29,203	3,439	-40.41	-	-	6,200	-	1,000	4,320	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ENOB Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Operating Expenses
General and administrative	$ 7,652,379	$ 3,796,057	$ 19,558,981	$ 12,365,960
Research and development	1,087,156	239,137	2,274,321	3,170,471
Intangible asset impairment (Note 5)	8,421,000	0	8,421,000	0
Depreciation and amortization	30,305	28,242	90,727	85,487
Total Operating Expenses	17,190,840	4,063,436	30,345,029	15,621,918
LOSS FROM OPERATIONS	(17,190,840)	(4,063,436)	(30,345,029)	(15,621,918)
Other Income (Expense)
Change in fair value of contingent consideration (Note 3)	486,500	0	486,500	0
Loss on extinguishment of debt	0	0	(120,018)	0
Loss on extinguishment of contingent consideration liability	0	0	0	(419,182)
Interest expense	(303,802)	(122,289)	(758,057)	(310,766)
Interest and other income (expense)	(16,272)	(142,571)	8,041	(133,938)
Total Other Income (Expense)	166,426	(264,860)	(383,534)	(863,886)
NET LOSS	$ (17,024,414)	$ (4,328,296)	$ (30,728,563)	$ (16,485,804)
BASIC LOSS PER SHARE	$ (0.16)	$ (0.08)	$ (0.39)	$ (0.30)
DILUTED LOSS PER SHARE	$ (0.16)	$ (0.08)	$ (0.39)	$ (0.30)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC	107,480,475	55,974,605	79,168,663	55,524,511
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED	107,480,475	55,974,605	79,168,663	55,524,511

ENOB Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Jun. 30, 2023
CURRENT ASSETS:
Cash	$ 312,697	$ 1,874,480
Prepaids and other assets	907,218	690,925
Total Current Assets	1,219,915	2,565,405
Property and equipment, net	488,915	508,989
OTHER ASSETS:
Definite life intangible assets, net	31,042	39,676
Indefinite life intangible assets	44,945,255	42,611,000
Goodwill	164,186,852	11,640,000
Deposits and other assets	21,742	21,741
Operating lease right-of-use assets	1,385,619	913,985
Total Other Assets	210,570,510	55,226,402
TOTAL ASSETS	212,279,340	58,300,796
CURRENT LIABILITIES:
Accounts payable – trade	7,990,631	5,296,823
Accrued expenses	3,754,976	723,173
Other current liabilities	519,427	184,733
Contingent consideration liability, current (Note 3)	1,006,438	0
Current portion of operating lease liabilities	483,226	193,422
Notes payable, net	3,418,621	4,624,947
Convertible notes payable	3,700,694	0
Total Current Liabilities	20,874,013	11,023,098
NON-CURRENT LIABILITIES:
Operating lease liabilities, net of current portion	970,353	775,587
Contingent consideration liability, noncurrent (Note 3)	19,064,562	0
Deferred tax liability	2,774,856	0
Total Non-Current Liabilities	22,809,771	775,587
Total Liabilities	43,683,784	11,798,685
Commitments and Contingencies (Note 9)
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; zero shares issued and outstanding at March 31, 2024 and June 30, 2023	0	0
Common Stock, par value $0.0001, 350,000,000 shares authorized, 147,488,598 shares issued and outstanding at March 31, 2024, and 63,698,144 shares issued and outstanding at June 30, 2023	14,750	6,371
Additional paid-in capital	442,304,652	290,554,875
Accumulated deficit	(274,757,816)	(244,029,253)
Accumulated other comprehensive income (loss)	1,033,970	(29,882)
Total Stockholders’ Equity	168,595,556	46,502,111
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 212,279,340	$ 58,300,796

About Enochian Biosciences, Inc.

Enochian Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Enochian Biosciences, Inc.? What does ENOB stand for in stocks?

ENOB is the stock ticker symbol of Enochian Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Enochian Biosciences, Inc. (ENOB)?

As of Tue Apr 30 2024, market cap of Enochian Biosciences, Inc. is 84.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENOB stock?

You can check ENOB's fair value in chart for subscribers.

What is the fair value of ENOB stock?

You can check ENOB's fair value in chart for subscribers. The fair value of Enochian Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Enochian Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ENOB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Enochian Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether ENOB is over valued or under valued. Whether Enochian Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Enochian Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENOB.

What is Enochian Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, ENOB's PE ratio (Price to Earnings) is -1.56 and Price to Sales (PS) ratio is 1.95 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENOB PE ratio will change depending on the future growth rate expectations of investors.